# Janet Schnee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/janet-schnee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,395 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 25 |
| i10-index | 35 |
| Last Known Institution | Boehringer Ingelheim (United States) |
| OpenAlex ID | https://openalex.org/A5074299303 |
| ORCID iD | https://orcid.org/0000-0001-6041-5839 |
| Works | 56 |

## Researcher papers

- [Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure](https://scholariq.org/papers/cardiovascular-and-renal-outcomes-with-empagliflozin-in-heart-failure/)
- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial](https://scholariq.org/papers/effect-of-empagliflozin-on-worsening-heart-failure-events-in-patients-with-heart/)
- [Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function](https://scholariq.org/papers/cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across-the/)
- [Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction](https://scholariq.org/papers/effect-of-empagliflozin-in-patients-with-heart-failure-across-the-spectrum-of/)
- [Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial](https://scholariq.org/papers/evaluation-of-the-effects-of-sodium-glucose-co-transporter-2-inhibition-with/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cell Adhesion Molecules Research](https://scholariq.org/topics/cell-adhesion-molecules-research/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

## Researcher university

- [Boehringer Ingelheim (United States)](https://scholariq.org/institutions/boehringer-ingelheim-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.